Abstract
Gynecological cancer management remains challenging and a better understanding of molecular mechanisms that lead to carcinogenesis and development of these diseases is needed to improve the therapeutic approaches. The Na+/H+ exchanger regulatory factor 1 (NHERF1) is a scaffold protein that contains modular protein-interaction domains able to interact with molecules with an impact on carcinogenesis and cancer progression. During recent years, its involvement in gynecological cancers has been explored, suggesting that NHERF1 could be a potential biomarker for the development of new targeted therapies suitable to the management of these tumors. This comprehensive review provides an update on the recent study on NHERF1 activity and its pathological role in cervical and ovarian cancer, as well as on its probable involvement in the therapeutic landscape of these cancer types.
Highlights
Margherita Sonnessa 1†, Sara Sergio 2†, Concetta Saponaro 1*, Michele Maffia 2, Daniele Vergara 2, Francesco Alfredo Zito 1 and Andrea Tinelli 3
It has long been clear that Na+/H+ exchanger regulatory factor 1 (NHERF1) exerts an important role in the regulation of signal transduction pathways acting as a scaffold protein
NHERF1 has been found overexpressed in breast cancer, schwannoma, hepatocellular carcinoma and other human tumors
Summary
Margherita Sonnessa 1†, Sara Sergio 2†, Concetta Saponaro 1*, Michele Maffia 2, Daniele Vergara 2, Francesco Alfredo Zito 1 and Andrea Tinelli 3. Relevance of NHERF1 Protein in Gynecological Tumors. One of these scaffold proteins with a well-established role in the regulation of cell signaling is the protein sodium/ hydrogen exchanger regulatory factor 1 (NHERF1). Phosphorylation at serine 77 the PDZ I domain impairs NHERF1 affinity for plasma membrane proteins influencing its subcellular localization [21].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have